Mizuho Upgrades Myriad, Citing Medicare Reimbursement and 'Overstated' Competitive Pressures | GenomeWeb

NEW YORK (GenomeWeb News) – Mizuho Securities today upgraded shares of Myriad Genetics to a Buy rating, citing an increase in Medicare reimbursements for the BRACAnalysis test, as well as stabilized competition, and several potential positive catalysts over the next year to 24 months.

Analyst Peter Lawson upgraded the company's stock from a prior Neutral rating and raised his 12-month price target on Myriad's shares to $50 from $40.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.